PharmAust (ASX:PAA) posted positive preliminary results in experiments aimed at inhibiting the virus that causes COVID-19. PharmAust, which traditionally is focused on repurposing existing drugs for cancer therapy, is...
PharmAust (ASX:PAA) achieved a successful outcome in a Phase 2 trial investigating the anti-cancer effects of its monepantel tablets in dogs with treatment naïve B-cell lymphoma. Following 14 days of monepantel tablet...
PharmAust (ASX:PAA) is gearing up to begin a pivotal Phase 2 study in Australia with its lead veterinary drug candidate, monepantel, for the treatment of lymphoma in canines, which if successful, could open the door to...